Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
Related Posts
Bach E, Breschi A, Wang Y, Carroll MK, Luk W, Han A, Short S, Cimermančič P, Drake KA, Cook LJ, Snyder T, Smith TJ, Yeaman[...]
Mbala-Kingebeni P, Boum Y, Fallah MP, Wilson B, Belizaire MR, Hoff NA, Sprecher A, Hensley LE, Kindrachuk J, Rimoin AW. Bundibugyo Ebola in DR Congo[...]
Appa A, Javanbakht M, Spinelli M, Heise MJ, Steiner G, Bolanos R, Okochi H, Gorbach P, Gandhi M. Hair Testing to Detect Long-term Methamphetamine Use[...]